Perioperative Management of Anticoagulation

  • Scott Kaatz
  • David G. Paje


Managing antithrombotic agents in patients undergoing surgery is a common clinical challenge, often requiring temporary interruption of treatment prior to the procedure. Antithrombotic agents can generally be grouped into anticoagulants and antiplatelet agents.


International Normalize Ratio Antiplatelet Therapy Mechanical Heart Valve Antithrombotic Agent CHADS2 Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1.  1.
    Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):299S-339S.PubMedCrossRefGoogle Scholar
  2.  2.
    United States National Institute of Health. July 7, 2010.
  3.  3.
    Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001;285(22):2864-2870.PubMedCrossRefGoogle Scholar
  4.  4.
    Kaatz S, Douketis JD, Zhou H, Gage BF, White RH. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost. 2010;8(5):884-890.PubMedGoogle Scholar
  5.  5.
    Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152(9):578-589.PubMedGoogle Scholar
  6.  6.
    Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164(12):1319-1326.PubMedCrossRefGoogle Scholar
  7.  7.
    Jeske AH, Suchko GD. Lack of a scientific basis for routine discontinuation of oral anticoagulation therapy before dental treatment. J Am Dent Assoc. 2003;134(11):1492-1497.PubMedGoogle Scholar
  8.  8.
    White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995;122(1):40-42.PubMedGoogle Scholar
  9.  9.
    Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110(12):1658-1663.PubMedCrossRefGoogle Scholar
  10. 10.
    Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):141S-159S.PubMedCrossRefGoogle Scholar
  11. 11.
    Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost. 2005;94(3):528-531.PubMedGoogle Scholar
  12. 12.
    Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5(11):2211-2218.PubMedCrossRefGoogle Scholar
  13. 13.
    Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American society of regional anesthesia and pain medicine evidence-based guidelines (third edition). Reg Anesth Pain Med. 2010;35(1):­64-101.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  1. 1.General Internal MedicineHenry Ford HospitalDetroitUSA

Personalised recommendations